We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

New Stent Uses Revolutionary Biomaterial

By HospiMedica staff writers
Posted on 31 Oct 2007
A revolutionary new biomaterial is being used to develop biodegradable stents for use in cardiac surgery.

Researchers at the New Jersey Center for Biomaterials (NJCBM, Piscataway, USA) at Rutgers University (Newark, NJ, USA) developed a library of degradable polymers comprising 10,000 theoretically possible compositions and applied combinatorial methods to identify the best possible biomaterial for the new stent. More...
The resulting biodegradable, biocompatible polymer is exceptionally strong and highly suitable for stent applications. In addition, the material was designed to be radio-opaque, a property critical to the proper placement of the stent in the artery.

The new stent based on the polymer's specifications is being designed and tested by REVA Medical (San Diego, CA, USA), and is intended to act as a temporary scaffold to support the blood vessel during the healing process and maintain blood flow. It subsequently dissolves, leaving the patient free of any permanent implant. The REVA Endovascular Study of a Bioresorbable Coronary Stent (RESORB) trial is evaluating the stents safety in approximately 30 patients at multiple sites in Germany and Brazil.

"Our unconventional discovery process integrates combinatorial polymer libraries, high-throughput testing, and computational modeling. This results in a much faster path to prototype development and a reduction in the cost and risk associated with the use of new, proprietary biomaterials,” said lead investigator Professor Joachim Kohn, director of the NJCBM.

RESORB is a non-randomized study of the resorbable stent with an initial assessment of major adverse cardiac events (MACE) at 30 days and a follow-up period of five years.


Related Links:
New Jersey Center for Biomaterials
Rutgers University
REVA Medical

Gold Member
12-Channel ECG
CM1200B
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Digital Radiography System (Ceiling Free)
Digix CF Series
New
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.